Dr Ibrahim Khadra

Publications

Formulation of polycaprolactone meshes by melt electrospinning for controlled release of daunorubicin in tumour therapy

Obeid Mohammad A, Akil Lina, Abul-Haija Yousef M, Khadra Ibrahim

Colloids and Surfaces A: Physicochemical and Engineering Aspects Vol 699 (2024)

https://doi.org/10.1016/j.colsurfa.2024.134873

A novel simulated media system for in vitro evaluation of bioequivalent intestinal drug solubility

Abuhassan Qamar, Silva Maria Inês, Abu-Rajab Tamimi Rana, Khadra Ibrahim, Batchelor Hannah K, Pyper Kate, Halbert Gavin W

European Journal of Pharmaceutics and Biopharmaceutics Vol 199 (2024)

https://doi.org/10.1016/j.ejpb.2024.114302

Characterization of ciprofloxacin-loaded polymeric fiber mats prepared by meltelectrospinning

Obeid Mohammad A, Akil Lina, A Aljabali Alaa, Khadra Ibrahim

Macromolecular Materials and Engineering Vol 309 (2024)

https://doi.org/10.1002/mame.202300376

Structured solubility behaviour in fed simulated intestinal fluids

Silva Maria Inês, Khadra Ibrahim, Pyper Kate, Halbert Gavin W

European Journal of Pharmaceutics and Biopharmaceutics Vol 193, pp. 58-73 (2023)

https://doi.org/10.1016/j.ejpb.2023.10.017

The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing

Obeid Mohammad A, Haifawi Saja, Khadra Ibrahim

International Journal of Pharmaceutics: X Vol 5 (2023)

https://doi.org/10.1016/j.ijpx.2023.100168

Study of in vitro poorly soluble drug solubility into fasted state simulated intestinal fluid reflective of in vivo gastrointestinal variability

McKinnon Zoe, Batchelor Hannah, Khadra Ibrahim, Halbert Gavin

British Journal of Pharmacy Vol 8 (2023)

https://doi.org/10.5920/bjpharm.1380

More publications

Research Interests

1-    Oral Drug Delivery/Formulation

 Orodispersible thin films (OTFs) were first established as breath fresheners and have since progressed to the delivery of active pharmaceutical ingredients (APIs). Composed principally of one or more water soluble, film-forming polymers, OTFs dissolve very rapidly in contact with saliva, releasing the active ingredient(s) without the need to chew or drink water. This makes them ideally suited to elderly or paediatric populations, who may have difficulty swallowing other solid oral dosage forms such as tablets or capsules.

 This is a growing area with a lot of industrial interest and lack of regulatory information and quick turn over for generic API; therefore the focus will be on the  following area:

-       Tatse Masking of API

-       The use of sweetener and flavour as a taste mask strategy

-       Dissolution assays and Biowavier

-       Thin film stability following the ICH guidelines

-       The use of different film former polymer for different purposes (IR, SR, and wound care application)

2-    Oral Biopharmaceutics

As most drugs are taken orally, as tablets or capsules for example. However, designing these pharmaceutical products in such a way that the active ingredient is absorbed at an appropriate rate and extent by the gut is far from easy. Therefore to be able to enhance the understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients.

This is another area of industrial and regulatory interest for which I will follow and continue the research generated and initiated in the oral biopharmaceutical tools project “Orbito” – we will also collaborate with our current industrial partners e.g. GSK, Pfizer, AZ, Novartis and others, and will be linked to colleague in CMAC (Professor Joop Ter Horst, CRUK (Professor Gavin Halbert) and also with the regulatory authorities in UK, Europe and USA.

The  focus will be on the following:

-       API physicochemical characterization

-      Drug solubility in human gastric and intestinal fluids “fed and fasted state” using the DOE approach

-       Develop small-scale tests for dissolution, nucleation and supersaturation.

-       Develop of predictive tools that the industrial partners can use to predict the behavior of their API.

3-    Extrusion, 3D and Chocolate Printing

 The applications of three dimensional (3D) printing in the field of pharmaceutical science and medicine are growing rapidly and the technique generates numerous benefits currently and also very promising potential applications in the near future such as drug discovery and delivery and tissue fabrication. 3D printing technology offers many advantages, for example, it permits customization of products and therefore it can be applied on a number of areas, such as drug delivery or tissue engineering.

The work in this area started and project with a leading Pharamceutical Compnay has been initiated which focus on the extrusion of drug loaded filament and the use of 3D printing technology to print a design for female health care.

Also the use of chocolate as drug delivery system for pediatric application is another growing area, the chocolate printer was developed in house and ready to use. This work is coordinated and led by Professor Clive Wilson and myself.

Professional Activities

University of Strathclyde (Event)

Chair

8/2022

EDAN Annual Conference

Speaker

2/5/2022

UNGAP Meeting

Speaker

1/3/2022

University of Strathclyde (Event)

Advisor

1/2022

Palestine Syndicate of Pharmacists (External organisation)

Advisor

1/1/2022

Strathclyde Institute Of Pharmacy And Biomedical Sciences (Organisational unit)

Member

12/2021

More professional activities

Projects

GiBio Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture (EPSRC Strategic equipment)

Batchelor, Hannah (Principal Investigator) Florence, Alastair (Co-investigator) Horan, Linda (Co-investigator) Khadra, Ibrahim (Co-investigator) McArthur, Stephen (Co-investigator)

01-Jan-2022 - 30-Jan-2025

DTP 2224 University of Strathclyde | Abu-Rajab Tamimi, Rana

Khadra, Ibrahim (Principal Investigator) Batchelor, Hannah (Co-investigator) Abu-Rajab Tamimi, Rana (Research Co-investigator)

01-Jan-2022 - 01-Jan-2026

Understanding long-term stability of solid pharmaceutical dosage forms by characterisation

Markl, Daniel (Principal Investigator) Khadra, Ibrahim (Co-investigator)

01-Jan-2021 - 31-Jan-2024

Industrial Case Account - University of Strathclyde 2020 | Jesney, Hannah

Markl, Daniel (Principal Investigator) Khadra, Ibrahim (Co-investigator) Jesney, Hannah (Research Co-investigator)

01-Jan-2020 - 01-Jan-2024

Biocompatible silk hydrogels as tunable stem cell constructs for the treatment of stroke. (skype)

Carswell, Hilary (Principal Investigator) Seib, Philipp (Co-investigator) Khadra, Ibrahim (Research Co-investigator)

01-Jan-2020 - 30-Jan-2023

Combined use of in-vitro and in-silico models for drug discovery

Khadra, Ibrahim (Principal Investigator)

01-Jan-2020 - 31-Jan-2024

More projects